Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer
暂无分享,去创建一个
Jun Luo | A. D. De Marzo | E. Corey | T. Lotan | S. Yegnasubramanian | M. Haffner | H. Tsai | P. Nelson | J. Woo | Michael C. Haffner | K. Asrani | T. Vidotto | B. Hanratty | Ilsa Coleman | Alba F C Torres
[1] J. Sage. Faculty Opinions recommendation of SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[2] P. Meltzer,et al. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets , 2020, Clinical Epigenetics.
[3] D. Cao,et al. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56. , 2020, Pathology, research and practice.
[4] R. Shi,et al. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer , 2019, bioRxiv.
[5] P. Nelson,et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.
[6] W. Isaacs,et al. Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. , 2019, JCO precision oncology.
[7] Yi Mi Wu,et al. Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.
[8] C. Rudin,et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.
[9] Yonggang Zheng,et al. Nerfin-1 represses transcriptional output of Hippo signaling in cell competition , 2019, eLife.
[10] W. Isaacs,et al. Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis. , 2018, The American journal of pathology.
[11] A. Sboner,et al. CD38 is methylated in prostate cancer and regulates extracellular NAD+ , 2018, Cancer & Metabolism.
[12] Yanqing Wang,et al. Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. , 2018, Human pathology.
[13] Joshua M. Stuart,et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Antonarakis,et al. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer , 2018, Prostate Cancer and Prostatic Diseases.
[15] Wenchao Zhao,et al. YAP knockdown inhibits proliferation and induces apoptosis of human prostate cancer DU145 cells. , 2017, Molecular medicine reports.
[16] J. Bishop,et al. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors , 2018, The American journal of surgical pathology.
[17] E. Davicioni,et al. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma , 2017, BMC Cancer.
[18] Michael D. Nyquist,et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.
[19] P. Worley,et al. mTORC1 loss impairs epidermal adhesion via TGF-&bgr;/Rho kinase activation , 2017, The Journal of clinical investigation.
[20] M. Rugge,et al. MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical–pathological features and outcome , 2017, Virchows Archiv.
[21] V. Velcheti,et al. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer , 2017, Oncotarget.
[22] P. Illei,et al. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity , 2017, The American journal of surgical pathology.
[23] Jiaoti Huang,et al. FOXA2 is a Sensitive and Specific marker for Small Cell Neuroendocrine Carcinoma of the Prostate , 2017, Modern Pathology.
[24] P. Nelson,et al. LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.
[25] T. Kameya,et al. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. , 2017, Gynecologic oncology.
[26] Faqian Li,et al. mASH1 is Highly Specific for Neuroendocrine Carcinomas: An Immunohistochemical Evaluation on Normal and Various Neoplastic Tissues. , 2017, Archives of pathology & laboratory medicine.
[27] C. Collins,et al. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. , 2017, European urology.
[28] Hiroshi I. Suzuki,et al. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer , 2016, Cancer science.
[29] S. Ishikawa,et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors , 2016, Cancer science.
[30] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[31] T. Buhl,et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas , 2015, International journal of cancer.
[32] L. Chin,et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. , 2016, Cancer discovery.
[33] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[34] R. Lloyd,et al. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. , 2015, American journal of clinical pathology.
[35] R. Vessella,et al. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas , 2015, Clinical Cancer Research.
[36] M. Karin,et al. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis , 2015, Genes & development.
[37] P. Nelson,et al. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.
[38] P. Nelson,et al. ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. , 2015, Cancer cell.
[39] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[40] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[41] M. Rubin,et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.
[42] Wennuan Liu,et al. Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.
[43] M. Raffeld,et al. Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. , 2013, Experimental and molecular pathology.
[44] Robert Gentleman,et al. Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..
[45] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[46] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[47] J. Hicks,et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy , 2012, Cancer.
[48] Robert H. Bell,et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer , 2012, The Journal of pathology.
[49] Sven Laur,et al. Robust rank aggregation for gene list integration and meta-analysis , 2012, Bioinform..
[50] Robert C. Thompson,et al. Negative regulation of Yap during neuronal differentiation. , 2012, Developmental biology.
[51] Jindan Yu,et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. , 2012, Genes & development.
[52] M. Gerstein,et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.
[53] Y. Yatabe,et al. Molecular and Cellular Pathobiology Mir-375 Is Activated by Ash1 and Inhibits Yap1 in a Lineage-dependent Manner in Lung Cancer , 2022 .
[54] Martin J. Aryee,et al. Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences , 2011, BMC Genomics.
[55] C. Bieberich,et al. ERG gene rearrangements are common in prostatic small cell carcinomas , 2011, Modern Pathology.
[56] J. Cuzick,et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.
[57] H. Rui,et al. RB-pathway disruption in breast cancer , 2010, Cell cycle.
[58] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[59] R. Kolde,et al. Mining for coexpression across hundreds of datasets using novel rank aggregation and visualization methods , 2009, Genome Biology.
[60] Steve Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[61] E. Montgomery,et al. Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.
[62] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[63] Li Li,et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.
[64] A. DeMarzo,et al. Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation , 2006, Nucleic acids research.
[65] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[66] M. Campbell,et al. PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.
[67] Tsuey-Ming Chen,et al. Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.
[68] J. Quinn,et al. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. , 2000, Cancer research.